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Abstract
Background Interferon (IFN) alpha is one of the central
agents in immunotherapy for renal cell carcinoma (RCC).
It acts by binding to the IFN-alpha receptor (IFNAR). We
previously reported that increased tumor expression of
IFNAR2 mRNA was associated with the metastatic
potential and progression of RCC, as well as with a poor
response of metastatic RCC to IFN-alpha therapy. This
study investigated the inﬂuence of serum IFNAR2 in RCC
patients.
Methods We measured serum IFNAR2 mRNA levels and
quantiﬁed IFNAR mRNA expression in paired tumor and
non-tumor tissues from the surgical specimens of 66 con-
secutive RCC patients by the real-time reverse transcrip-
tion polymerase chain reaction (RT-PCR). We also
measured phosphorylated Akt (Ser-473) and phosphory-
lated-S6 ribosomal protein (Ser-235/236) proteins levels in
paired tumor and non-tumor tissues of patients with met-
astatic RCC by Western blotting.
Results The serum level of IFNAR2 mRNA was not
associated with its tumor tissue level. Serum IFNAR2
mRNA was positively correlated with tumor size
(P\0.05), but not with tumor grade, pT stage, metastasis,
microscopic vascular invasion, or serum C-reactive pro-
tein. Serum levels of IFNAR2 mRNA were signiﬁcantly
higher in patients with a good response to IFN-alpha ±
sorafenib than in those with a poor response (P\0.0001).
Tumor tissue IFNAR2 mRNA levels and phosphorylated-
S6 ribosomal protein (Ser-235/236) levels were associated
with metastatic potential (P\0.001 and P\0.01,
respectively), and patients with a low IFNAR2 mRNA
level and low phosphorylated Akt (Ser-473) protein level
in the primary tumor showed a good response to IFN-a ±
sorafenib (IFN-a ± Sor: CR-PR) (P\0.01 and P\0.05,
respectively). Kaplan–Meier survival analysis showed that
a higher serum IFNAR2 mRNA level was associated with
longer overall survival of treated patients (P\0.05), while
a higher tumor tissue IFNAR2 mRNA level was related to
shorter overall survival (P\0.01).
Conclusions Our ﬁndings suggest that a high serum level
of IFNAR2 mRNA may be a useful marker for predicting
the response of metastatic RCC to IFN-alpha ± sorafenib
therapy.
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Introduction
Localized renal cell carcinoma (RCC) is generally con-
sidered to be a surgical disease. However, almost 30% of
the patients who present with limited disease and undergo
surgery develop metastasis during the next 3 years [1]. The
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2–3% of all adult malignancies. Around 40% of RCC
patients die of metastasis, because of the high frequency of
metastasis at diagnosis and relapse following nephrectomy
[2]. Patients with distant metastases have a very poor
prognosis, and their 5-year survival rate is less than 10%
[2]. Clear cell RCC is considered to be an immunogenic
tumor [3], with immunocytokine therapy being the main-
stay of treatment [4], while it is notoriously resistant to
chemotherapy and radiotherapy [2]. Targeting novel path-
ways associated with the evolution of malignancy may lead
to an improved outcome for patients with RCC. Novel
treatment options include immunotherapy [5], monoclonal
antibodies [6], anti-angiogenesis therapy [7], and inhibitors
of mammalian target of rapamycin (mTOR) [8–10].
Japanese patients who receive immunocytokine therapy
including interferon alpha (IFN-a) show a better response
and survival compared with American or European patients
[11]. With the advent of molecular-targeting therapy, the
use of sorafenib and sunitinib for RCC has been covered by
the Japanese national health insurance system since 2008.
Recently, Motzer et al. [12] identiﬁed ﬁve prognostic
factors for RCC, which are known as the Memorial Slone-
Kettering Cancer Center (MSKCC) classiﬁcation (Kar-
nofsky performance status, time from diagnosis of RCC to
treatment or recurrence, serum lactate dehydrogenase,
corrected serum calcium, and hemoglobin). The MSKCC
classiﬁcation is correlated with the overall survival of
patients with metastatic RCC receiving IFN-a as initial
systemic therapy. It has the potential to be employed for
predicting the efﬁcacy of immunocytokine therapy, and it
may also be useful for predicting the response to molecu-
lar-targeting therapy. Recently, a number of molecular
markers have been investigated in RCC patients to assess
both their predictive value and their potential as therapeutic
targets. Identiﬁcation of new targets may lead to an
improvement in the outcome of RCC, but no biomarkers
have been established so far.
Individual variations of mRNA expression can have an
important inﬂuence [13]. We previously reported that
increased expression of IFNAR2 mRNA in tumor tissue is
associated with the metastatic potential and progression of
RCC and with a poor response to IFN-a therapy [14]. Our
previous study also showed that a 102-KDa IFNAR2c
protein, a functional domain of IFNAR2, is more highly
expressed in the primary tumors compared with the non-
tumor tissues of patients with metastatic RCC, but not
localized RCC, indicating that the main component of IF-
NAR2 is the long form of IFNAR2c and that this protein
may be important in the progression of RCC [14]. However,
the inﬂuence of circulating (serum) IFNAR2 mRNA in
patients with RCC has not been elucidated. In the present
study, we examined serum levels of IFNAR2 mRNA, as
well as the IFNAR2 mRNA levels in corresponding tumor
tissue and non-tumor tissue samples, by the real-time
reverse transcription polymerase chain reaction (RT-PCR).
The relations among serum and tumor tissue levels of IF-
NAR2 mRNA and various clinicopathologic features of
RCC patients were also examined. Furthermore, we inves-
tigated whether IFNAR2 mRNA could be used to predict
the response of metastatic RCC to IFN-a ± sorafenib
therapy. It was hoped that the information obtained might
contribute to elucidation of the role of IFNAR2 in RCC.
Materials and methods
Patients, blood samples, and tissue specimens
We studied 66 consecutive Japanese patients (39 men and
27 women) aged 32–82 years (mean age: 62.9 years), who
were newly diagnosed with clear cell RCC from 2008 to
2010. All patients routinely underwent imaging with CT
and/or MRI for preoperative staging prior to radical
nephrectomy. The postoperative follow-up period ranged
from 2 to 35 months (median: 19 months). Surgery was
done before the patients received any other therapy.
A peripheral whole blood sample (10 ml) was collected
from each patient and was diluted in PBS with 2 mM
EDTA. Then, peripheral blood mononuclear cells (PBMC)
were separated using Ficol-Hypaque medium (Biocoll,
Berlin, Germany) and gradient centrifugation and stored at
-80C for future use. Total RNA was isolated with an
RNeasy kit (Qiagen, Hamburg, Germany), including a
DNA digestion step using the RNase-free DNase set.
In every patient, three different tumor tissue specimens
andvariouspartsofthenon-neoplastickidneywereharvested
for this study and stored at -80C, as described previously
[13–15].Thetumorgradeandclinicalstageweredetermined
according to the Fuhrman grading system and the TNM
classiﬁcation, respectively [16, 17]. This study was con-
ducted in accordance with the Helsinki Declaration, and
approval of the Dokkyo Medical University Hospital insti-
tutional review board was obtained. In addition, each patient
signedaconsentformthatwasapprovedbytheCommitteeon
Human Rights in Research of our institution.
Postoperative immunotherapy with IFN-a was given to
26 patients with extra-renal involvement. These patients
received 3, 5, or 6 million units of natural human IFN-a
intravenously or intramuscularly two or three times a week
until tumor progression occurred. If the tumor was refrac-
tory to IFN-a monotherapy (progressive disease; PD),
concomitant treatment with IFN-a and sorafenib (400 mg/
day) was performed [18].
The doses of IFN-a and sorafenib were decreased if
grade 3/4 toxicity occurred. Peripheral whole blood
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123samples (10 ml) were obtained every 2 or 3 months from
each metastatic RCC patient on treatment with IFN-a ±
sorafenib. Tumor response was assessed according to RE-
CIST criteria [19].
Real-time RT-PCR
Total RNA was puriﬁed from all 66 sets of serum, tumor
tissue samples, and non-tumor tissue samples with an RNA
preparation kit (‘‘High Pure RNA Kit’’; Roche Diagnostic
Ltd., Germany) and was used as the template for cDNA
synthesis. A 100-ll reaction mixture containing 1 mg of
random hexamers and 100 units of MMLV reverse trans-
criptase was incubated at 25C for 10 min, at 42C for
30 min, and then at 99C for 5 min. The IFNAR gene
expression proﬁle was analyzed with an ABI PRISM 7700
Sequence Detection System (Applied Biosystems, Foster
City, CA) using the SYBR Green method. The following
primers were employed to amplify the b-actin gene after
conﬁrming their speciﬁcity: sense; 50-CTGGCATCGT
GATGGACTCCGG-30; anti-sense, 50-GTGGATGCCAC
AGGACTCCATG-30. The primers used for IFNAR1 and
IFNAR2 have been previously reported [14]. Real-time RT-
PCR was performed in a 25-ll reaction mixture containing
20 ng of sample cDNA, 100 nM sense primer, 100 nM anti-
sense primer, and 12.5 ll of SYBR Green PCR Master Mix
(Applied Biosystems), with 45 cycles of 95C for 15 s and
60C for 1 min. A standard curve for each mRNA was
generated using ﬁvefold dilutions of a control RNA sample
(259,5 9,1 9, 0.29, and 0.049). The expression of each
IFNAR mRNA was calculated as a ratio to that of b-actin in
the serum, tumor tissue, and corresponding normal tissue
samples to determine the relative level of expression [13,
14]. Individual variations of mRNA expression considered
to be important [13]. To investigate the inﬂuence of such
individual variations in the expression of IFNAR1 mRNA
and IFNAR2 mRNA in the blood and tissues, we compared
the expression of these mRNAs in serum and paired sam-
ples of tumor and non-tumor tissues. For quantiﬁcation of
mRNA expression, the relative amounts of IFNAR1 and
IFNAR2 mRNAs in the tumors were calculated as a ratio of
the optical density of the bands for the tumor specimens to
the density of the bands for the corresponding normal tissue
specimens (T/N ratio) by densitometric analysis, as
described previously [13, 14]. The mean value for three
tissue samples was used, as described previously [13, 14].
We also measured the serum C-reactive protein (CRP) level
(normal\0.3 mg/dl) in each patient.
Western blotting
We could only perform Western blotting for 15 M1 tumors
and four M0 tumors. Samples of tumor tissue and normal
tissue were carefully dissected free of stromal tissue.
Western blotting for phosphorylated Akt (Ser-473), Akt,
and phosphorylated S6 ribosomal protein (Ser-235/236)
was carried out as described previously [15, 20, 21]. Brieﬂy,
50 lg of cytosolic protein was separated by SDS–PAGE on
12.5% gel and electrotransferred to a polyvinylidene
diﬂuoride membrane (Immobilon-P membrane; Millipore,
Bedford, MA). After the membrane was blocked, the bound
proteins were probed with an anti-rabbit monoclonal anti-
body for phosphorylated Akt (Ser-473) and an anti-rabbit
monoclonal antibody for Akt (Cell Signaling Technology,
Inc; PhosphoPlus Akt (Ser-473) Antibody Kit; # 9270,
Danvers, MA), as well as an anti-rabbit monoclonal anti-
body for phosphorylated S6 ribosomal protein (Ser-235/
236) (2F9) (Cell Signaling Technology, Inc; # 4856) and a
primary antibody for b-actin (Santa Cruz Biotechnology,
Santa Cruz, CA). Hela cells were used as the positive
control. Next, the membranes were washed and incubated
with horseradish peroxidase-conjugated secondary anti-
bodies. Bands of antibody-bound proteins were visualized
by chemiluminescence; the blotted membrane was scanned
for densitometry with a PDI imaging scanner (Agfa Japan,
Tokyo), and the data were analyzed with NIH Image soft-
ware. Expression of phosphorylated Akt (Ser-473),Akt, and
phosphorylated S6 ribosomal protein (Ser-235/236) was
calculated relative to that of b-actin in the tumor tissue
specimens and corresponding normal tissue specimens. For
quantiﬁcation of these proteins, the relative amount of
phosphorylated Akt (Ser-473), Akt, or phosphorylated S6
ribosomal protein (Ser-235/236) in tumor tissue was
expressed as a ratio of the optical density of the band for the
tumor tissue specimen to that for the corresponding normal
tissue specimen (set at 1.0) by densitometric analysis, as
described previously [15, 20, 21]. The mean values for
specimens of tumor and non-tumor tissue were calculated
from three experiments [15, 21].
Statistical analysis
Real-time RT-PCR and Western blotting data were ana-
lyzed by the Mann–Whitney U-test for comparisons
between two groups (pT stage, metastasis, microscopic
pathological vascular invasion, and serum CRP), while the
Kruskal–Wallis test was used to compare three groups
(histological grade and treatment effect) [13–15]. Spear-
man’s rank correlation coefﬁcient analysis was performed
to determine the relations between IFNAR2 mRNA
expression and the serum CRP level or tumor size. The
Kaplan–Meier method was used to estimate survival, and
differences of survival were assessed by the log-rank test.
In all analyses, a P value of less than 0.05 was considered
signiﬁcant. Data were analyzed with commercially avail-
able software.
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Serum IFNAR mRNA and characteristics of RCC
Although the preoperative serum IFNAR2 mRNA level was
not related to the IFNAR2 mRNA level in tumor tissues
(Fig. 1a)orthepreoperativeserumCRPlevel(Fig. 1b),there
was a weak positive correlation between serum IFNAR2 and
tumor size (r
2 = 0.121, P = 0.0056, Fig. 1c).
The preoperative serum IFNAR2 mRNA level was not
associated with the histological grade of RCC
(mean ± S.D., grade 1, 1.38 ± 0.80; grade 2, 1.41 ± 0.71;
grade 3, 1.36 ± 0.78, P = 0.9390, Fig. 2a), the pT stage
(pT1–2, 1.35 ± 0.67; pT3–4, 1.47 ± 0.80, P = 0.7692,
Fig. 2b), tumor metastasis (M0, 1.37 ± 0.74; M1,
1.49 ± 0.71, P = 0.5058, Fig. 2c), or microscopic vascu-
lar invasion (v(-), 1.36 ± 0.69; v(?), 1.55 ± 0.80,
P = 0.3886, Fig. 2d).
The preoperative serum level of IFNAR1 mRNA was
not associated with the IFNAR1 mRNA level in tumor
tissues, the preoperative serum CRP level, tumor size,
histological grade, pT stage, tumor metastasis, or micro-
scopic vascular invasion (data not shown).
A higher preoperative serum CRP level was associated
with local invasion (pT1–2, 0.24 ± 0.30; pT3–4, 3.50 ±
5.48, P\0.0001), metastatic disease (M0, 0.39 ± 0.63;
M1, 4.11 ± 6.09, P = 0.0002, and microscopic vascular
invasion (v(-), 0.49 ± 0.73; v(?), 4.11 ± 6.41,
P = 0.0217), but not with the histological grade of RCC
(grade 1, 1.18 ± 3.03; grade 2, 0.83 ± 1.47; grade 3,
4.49 ± 7.74, P = 0.0771) (data not shown).
Tumor expression of IFNAR mRNA and characteristics
of RCC
The IFNAR2 mRNA level in tumor tissue specimens was
correlated with the histological grade of RCC (grade 1,
0.82 ± 0.46; grade 2, 1.12 ± 0.86; grade 3, 1.97 ± 1.61,
P = 0.0480, Fig. 3a), pT stage (pT1–2, 0.94 ± 0.59;
pT3–4, 1.58 ± 1.37, P = 0.0111, Fig. 3b), tumor
Fig. 1 Spearman rank correlation coefﬁcient relationship between
mRNA expression levels of serum IFNAR2 mRNA and other factors.
X axis is an independent variable. Y axis is a dependent variable.
Serum IFNAR2 mRNA levels were associated with tumor size (c),
but not with the IFNAR2 mRNAs in tumors (a) and serum CRP
levels (b)
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123metastasis (M0, 0.89 ± 0.61; M1, 1.83 ± 1.39,
P = 0.0009, Fig. 3c), microscopic vascular invasion (v(-),
0.97 ± 0.70; v(?), 1.54 ± 1.39, P = 0.0392, Fig. 3d), and
serum CRP (normal,\0.30 mg/dl; high CRP, 1.63 ± 1.35;
low CRP, 0.88 ± 0.61; P = 0.0154, Fig. 3e). In contrast,
there was no relationship between IFNAR1 mRNA
expression and the histological grade (grade 1, 1.07 ±
0.79; grade 2, 1.75 ± 3.79; grade 3, 0.90 ± 0.67,
P = 0.7472), stage (pT1–2, 0.87 ± 0.58; pT3–4, 2.30 ±
4.61, P = 0.2439), tumor metastasis (M0, 0.74 ± 0.51;
M1, 3.07 ± 5.18, P = 0.0735), microscopic vascular
invasion (v(-), 1.59 ± 3.91; v(?), 1.54 ± 1.08, P =
0.9736), or serum CRP (normal,\0.30 mg/dl; high CRP,
2.50 ± 4.77; low CRP, 0.91 ± 0.71; P = 0.2646).
Tumor expression of phosphorylated Akt (Ser-473),
Akt, and phosphorylated S6 ribosomal protein (Ser-
235/236) and characteristics of RCC
We could only perform Western blotting for 15 M1 tumors
and four M0 tumors. The levels of phosphorylated Akt
(Ser-473) and phosphorylated S6 ribosomal protein (Ser-
235/236) were signiﬁcantly higher in M1 tumors than in
M0 tumors (3.93 ± 3.13, vs. 0.89 ± 0.40, P = 0.0257 and
3.82 ± 2.28 vs. 0.96 ± 0.84, P = 0.0079, respectively,
Fig. 4). In contrast, there was no difference of Akt
expression between M1 tumors and M0 tumors (1.13 ±
0.26, vs. 1.48 ± 1.87, P = 0.3662).
Preoperative serum level of IFNAR2 mRNA showed a
weak negative correlation with tumor tissue levels of
phosphorylated Akt (Ser-473) (r
2 = 0.205, P = 0.0903,
Fig. 5a), but not with tumor tissue levels of AKT
(r
2 = 0.017, P = 0.6587) or phosphorylated S6 ribosomal
protein (Ser-235/236) (r
2 = 0.072, P = 0.3327, Fig. 5b).
On the other hand, tumor tissue levels of IFNAR2 mRNA
were positively associated with the levels of phosphory-
lated S6 ribosomal protein (Ser-235/236) (r
2 = 0.35,
P = 0.0202, Fig. 5d) and also showed a weak positive
correlation with phosphorylated Akt (Ser-473) (r
2 = 0.199,
P = 0.0959, Fig. 5c), but not with Akt (r
2 = 0.001,
P = 0.9154). Although there was a positive correlation
between tumor tissue levels of phosphorylated Akt (Ser-
473) and phosphorylated S6 ribosomal protein (Ser-235/
236) (r
2 = 0.332, P = 0.0245, Fig. 5e), there was no
relationship between either of these two phosphorylated
proteins and Akt (data not shown).
Fig. 2 Serum levels for IFNAR2 mRNAs were not associated with
tumor grade (a), pT stage (b), metastasis (c), and pathological
microscopic vessel invasion (d). The median value is the central line,
the box is the interquartile range, the bars are the full range, and the
points are the outliers. Bold circled P values were obtained by
comparing the three groups with the Kruskal–Wallis test
Cancer Immunol Immunother (2011) 60:793–808 797
123Fig. 3 The IFNAR2 mRNA
levels in tumors were associated
with tumor grade (a), pT stage
(b), metastasis (c), pathological
microscopic vessel invasion (d),
and serum CRP levels (e). The
median value is the central line,
the box is the interquartile
range, the bars are the full
range, and the points are the
outliers. Bold circled P values
were obtained by comparing the
three groups with the Kruskal–
Wallis test
Fig. 4 Expression of phosphorylated Akt (Ser-473) (60 kDa), Akt
(60 kDa), phosphorylated S6 ribosomal protein (Ser-235/236)
(32 kDa), and beta actin (42 kDa) proteins in the primary tumor
tissues with metastatic lesions (M1) and without (M0) using Western
blotting. N non-tumor tissue, T primary tumor tissue with metastatic
lesions. Each number corresponds to a case number
798 Cancer Immunol Immunother (2011) 60:793–808
123Relationship between IFNAR2 mRNA, phosphorylated
Akt (Ser-473), Akt, or phosphorylated S6 ribosomal
protein (Ser-235/236) and the response to therapy
Kaplan–Meiersurvivalplotsfortwenty-sixmetastaticRCCs
treated with IFN-a monotherapy showed that the patients
with a good response to this agent had better progression-
free survival (Fig. 6a). Among the 21 patients refractory to
IFN-a, IFN-a ? Sor: CR-PR group had longer progression-
free survival than IFN-a ? Sor: SD-PD group (Fig. 6b).
Thus, the patients with a good response to IFN-a with/
without sorafenib had favorable overall survival (Fig. 6c).
Twenty-six patients with metastatic disease received
IFN-a as ﬁrst-line adjuvant therapy. If these patients
showed a poor response to IFN-a monotherapy, they
received concomitant treatment with IFN-a and sorafenib
(Sor) as second-line therapy. Five of the 26 patients
showed a complete or partial response to IFN-a alone
(IFN-a: CR-PR), while the other 21 patients received
concomitant IFN-a ? sorafenib as second-line therapy.
The ﬁve patients with a good response to IFN-a alone
(IFN-a: CR-PR) were low risk according to the MSKCC
criteria. There was no difference of the preoperative serum
IFNAR2 level between the patients with a good response to
IFN-a (IFN-a: CR-PR, 1.74 ± 0.53) and those with a poor
response, including stable disease or progressive disease
(IFN-a: SD-PD; 1.31 ± 0.59, P = 0.1263, Fig. 7a). Lower
tumor expression of IFNAR2 mRNA was related to a good
Fig. 5 Spearman rank
correlation coefﬁcient
relationship. X axis is an
independent variable. Y axis is a
dependent variable. Serum
IFNAR2 mRNA levels
inversely correlated with tumor
phosphorylated Akt (Ser-473)
(a), but not tumor
phosphorylated S6 ribosomal
protein (Ser-235/236) (b).
Tumor IFNAR2 mRNA levels
were associated with tumor
phosphorylated S6 ribosomal
protein (Ser-235/236) (c), and
weak positive correlation with
tumor phosphorylated Akt (Ser-
473) (d). Tumor phosphorylated
Akt (Ser-473) and
phosphorylated S6 ribosomal
protein (Ser-235/236) were
related each other (e)
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123response (IFN-a: CR-PR, 0.76 ± 0.40; IFN-a: SD-PD,
1.89 ± 1.38, P = 0.0345, Fig. 7b).
Among the 21 patients treated with IFN-a ? sorafenib,
eleven patients showed a good response (IFN-a ? Sor:
CR-PR), while the other 10 patients had stable disease or
progressive disease (IFN-a ? Sor: SD-PD). The back-
ground characteristics and the outcomes of the patients
receiving concomitant therapy with IFN-a ? sorafenib are
summarized in Table 1. A higher preoperative serum IF-
NAR2 level was correlated with a good outcome (IFN-
a ? Sor: CR-PR, 1.70 ± 0.39; IFN-a: CR-PR,
1.74 ± 0.53; IFN-a ? Sor: SD-PD, 0.88 ± 0.47,
P = 0.0013, Fig. 7e). In order to better assess the effect of
combination therapy, we combined the IFN-a : CR-PR
group and the IFN-a ? Sor: CR-PR group into a single
good response group (IFN-a ± Sor: CR-PR). The preop-
erative serum IFNAR2 level was signiﬁcantly higher in this
good response group than in the group with a poor response
to IFN-a ? sorafenib (INF-a ± Sor: CR-PR, 1.71 ± 0.42;
IFN-a ? Sor: SD-PD, 0.88 ± 0.47, P\0.0001) (Fig. 7c).
On the other hand, low tumor expression of IFNAR2
mRNA was related to a good response (IFN-a ? Sor: CR-
PR, 1.34 ± 1.09; IFN-a: CR-PR, 0.76 ± 0.40; IFN-
a ? Sor: SD-PD, 2.51 ± 1.46, P = 0.0064, Fig. 7f, IFN-a
± Sor: CR-PR, 1.16 ± 0.95; IFN-a ? Sor: SD-PD,
2.51 ± 1.46, P = 0.0027, Fig. 7d).
Interestingly, chronological analysis of serum IFNAR2
mRNA levels showed that these levels remained relatively
high in the IFN-a ± Sor: CR-PR group and remained lower
in the IFN-a ? Sor: SD-PD group (Fig. 8).
The IFN-a ? Sor: CR-PR group had lower phosphory-
lated Akt (Ser-473) levels than the IFN-a ? Sor: SD-PD
group (1.65 ± 1.08 vs. 5.54 ± 3.22, P = 0.0208, Fig. 9a).
Lower expression of phosphorylated S6 ribosomal protein
(Ser-235/236) tended to be associated with a better
response (IFN-a ± Sor: CR-PR, 2.50 ± 1.09; IFN-
a ? Sor: SD-PD, 4.72 ± 2.59, P = 0.1052, Fig. 9b). On
the other hand, expression of Akt was similar in both the
IFN-a ? Sor: CR-PR group and the IFN-a ? Sor: SD-PD
group (1.11 ± 0.19 vs. 1.16 ± 0.34, P = 0.9078).
Unlike IFNAR2 mRNA, serum and tissue levels of IF-
NAR1 mRNA were unrelated to the response to treatment
(data not shown).
Prognostic value of IFNAR2 mRNA, phosphorylated
Akt (Ser-473), and phosphorylated S6 ribosomal
protein (Ser-235/236)
The mean serum level of IFNAR2 mRNA and mean tumor
tissue levels of IFNAR2 mRNA, phosphorylated Akt (Ser-
473), and phosphorylated S6 ribosomal protein (Ser-235/
236) in M1 patients treated by IFN-a ± sorafenib were 1.39
Fig. 6 Survival curve in the patients with metastatic lesions (M1)
based on the treatment effects. a Progression-free survival curve in
M1 patients treated with IFN-a alone. One patient of IFN-a: CR-PR
group progressed gradually into progressive disease (PD) after partial
response (PR), but continued IFN-a monotherapy. Median survival
time in IFN-a: SD-PD group is 16.7 months. Survival time of IFN-a:
CR-PR group does not reach. b Progression-free survival curve in M1
patients after combination therapy with IFN-a plus sorafenib. Median
survival time in IFN-a ? Sor: SD-PD group is 4.3 months. Survival
time of IFN-a ? Sor: CR-PR group does not reach. c Overall survival
curve in M1 patients treated with IFN-a with/without sorafenib.
Median survival time in IFN-a ? Sor: SD-PD group is 15.6 months.
Survival time of IFN-a ± Sor: CR-PR group does not reach. P value
was analyzed by log-rank test
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123Fig. 7 The relationship between treatment effect and mRNA levels
of serum and tumor IFNAR2. The serum and tumor IFNAR2 mRNAs
levels in the IFN-a monotherapy (a, b), and IFN-a ± sorafenib
therapy (c–f). The median value is the central line, the box is the
interquartile range, the bars are the full range, and the points are the
outliers. Bold circled P values were obtained by comparing the three
groups with the Kruskal–Wallis test
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123(±0.60), 1.67 (±1.33), 3.72 (±3.12), and 3.63 (±2.24),
respectively. Patients were divided into two groups based
on these mean values (i.e., a high group and a low group),
as described previously [13–15, 21]. Kaplan–Meier sur-
vival plots for patients with low versus high levels of these
possible prognostic factors showed that a lower serum level
Table 1 Background of 26
metastatic RCCs treated with
IFN-a ± sorafenib (400 mg/
day)
ECOG PS* eastern cooperative
oncology group (ECOG)
performance status, MSKCC*
Memorial Sloen-Kettering
Cancer Center, Fav favorable
risk, Int intermediated risk,
Duration of IFN-a* duration of
IFN-a monotherapy, Duration
of pre-IFN-a* duration of IFN-a
monotherapy prior to IFN-a
plus sorafenib, Metastatic
lesions* PUL Lung, PLE
Pleura, HEP Liver, OSS Bone,
LYM lymph node, AE* adverse
events, HT hypertension, HFS
hand-foot syndrome
Option IFN-a alone IFN-a ? sorafenib
CR-PR
(n = 5)
CR-PR
(n = 11)
SD-PD
(n = 10)
Sex (male/female)
19/7
Years (median)
39–78 (63)
ECOG PS* (0/1/2)
17/7/2 5/0/0 8/3/0 4/4/2
MSKCC* (Fav/Int/Poor)
11/12/3 4/1/0 5/6/0 2/5/3
Duration of IFN-a* (mean:months) 3–29 (14.7)
Duration of pre-IFN-a* (mean:months) 1–27 (7.8)
Duration of IFN-a ? sorafenib
(mean:months)
1–23 (9.7)
Metastatic lesions* (numbers)
PUL
25 5 17 3
PLE
20 1 1
HEP
40 1 3
OSS
5 Radiation fo
bone lesions
02 3
LYM
80 4 4
Others
20 0 2
AE*: Grade 1/2 (numbers)
HT 0 14
Fatigue 3 9
Alopecia 0 13
Fever 4 8
HFS 0 6
Thrombocytopenia 2 4
Elevation of amylase and/or lipase 0 5
Others 2 9
AE*: Grade 3/4 (numbers)
HT 0 1
Fatigue 1 1
Alopecia 0 2
Fever 0 3
Thrombocytopenia 0 2
Elevation of ALT and AST 0 2
Erythema multiforme 0 1
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123of IFNAR2 mRNA (P\0.05), a higher tumor tissue levels
of IFNAR2 mRNA (P\0.01), phosphorylated Akt (Ser-
473) (P\0.05), and phosphorylated S6 ribosomal protein
(Ser-235/236) (P\0.05) were correlated with shorter
overall survival (OS) (Fig. 10a–d).
Discussion
There were ﬁve main ﬁndings of this study. First, the
preoperative serum level of IFNAR2 mRNA was correlated
with tumor size. Second, the tumor tissue levels of IF-
NAR2 mRNA and phosphorylated S6 ribosomal protein
(Ser-235/236) were positively correlated with each other,
and both were related to tumor metastatic potential. Third,
while the patients with a high preoperative serum level of
IFNAR2 mRNA showed a good response to IFN-a ± so-
rafenib (IFN-a ± Sor; CR-PR) and a longer overall sur-
vival, the patients with a low serum level and a high tumor
tissue level of IFNAR2 mRNA level showed a poor
response (SD-PD) and a shorter overall survival. Fourth,
the patients with a high serum level of IFNAR2 mRNA
throughout treatment showed a good response to IFN-a ±
Sor. Fifth, a high level of phosphorylated Akt (Ser-473),
but not a high level of phospho-S6 ribosomal protein (Ser-
235/236), in the primary tumor was related to a poor
response to IFN-a ± sorafenib. These ﬁndings suggest that
the serum level of IFNAR2 mRNA might be useful to
predict the efﬁcacy of IFN-a ± sorafenib therapy, while the
tumor tissue level of IFNAR2 mRNA could be associated
with metastatic potential and tumor resistance.
Combination therapy with IFN-a and sorafenib
While the efﬁcacy of combination therapy with IFN-a and
sorafenib needs clariﬁcation, the adverse effects of this
regimen are related to the doses of each agent and are not
additive [22–25]. We previously reported a good response
to combination therapy with IFN-a and half the usual dose
of sorafenib (400 mg/day rather than 800 mg/day) in
patients with IFN-a-resistant RCC, along with tolerable
adverse events [18].
It has also been reported that combined treatment with
IFN-a ? sorafenib suppresses proliferation and vascular
endothelial growth factor (VEGF) production by several
RCC cell lines more strongly than either agent alone [26,
27]. RCC is considered to be an immunogenic tumor [3],
since cytotoxic T lymphocytes recognize and selectively
kill autologous RCC cells, while tumor-speciﬁc T cells can
be detected in the blood of RCC patients [3]. Sorafenib is a
multikinase inhibitor targeting VEGF receptors 1–3,
PDGFb receptor, and Raf kinase, and it has both direct
antitumor activity and antiangiogenic activity [28]. In a
Fig. 8 Chronological analysis of serum IFNAR2 mRNA throughout
IFN-a ± sorafenib treatment; IFN-a ± Sor: CR-PR group (n = 12),
IFN-a ? Sor: SD-PD group (n = 7)
Fig. 9 The relationship between treatment effect and protein expres-
sion levels of Akt, phosphorylated Akt (Ser-473) (a) and phosphor-
ylated S6 ribosomal protein (Ser-235/236) (b). The relative
expression levels of targeted proteins in the primary tumor to those
in corresponding non-tumor portion, which was set to 1.0. Hela cell
was used as the positive control. The median value is the central line,
the box is the interquartile range, the bars are the full range, and the
points are the outliers
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123randomized phase III trial comparing sorafenib with pla-
cebo as second-line therapy for RCC, the response rate to
sorafenib was 10%, and the stable disease rate was 74%,
with the median progression-free survival time being
5.5 months in the sorafenib group versus 2.8 months in the
placebo group [29]. In addition to its immunomodulatory
effects, IFN-a also has direct antitumor activity as well as
antiangiogenic activity, including inhibition of VEGF [30].
Antitumor immunity is usually suppressed in tumor-bear-
ing mice because of the inﬂuence of regulatory T cells and
suppressive cytokines, such as TGF-b and IL-10 [31].
Takeuchi et al. recently reported that the synergistic effect
of sorafenib and IFN-a on RCC both in vitro and in tumor-
bearing mice was related to a combination of antitumor,
antiangiogenic, and immunologic responses [27]. In their
study, sorafenib had no effect on the levels of natural killer
(NK) cells, T cells, and regulatory T cells in the spleens of
tumor-bearing BALB/c mice, irrespective of the use of
IFN-a, while IFN-a showed weaker direct antitumor
activity than sorafenib but stimulated CTL, NK cells, and
tumor-inﬁltrating lymphocytes (which sorafenib did not),
so that a synergistic antiproliferative effect of these two
agents was demonstrated in vitro [27].
Although an additive effect of IFN-a to sorafenib ther-
apy in patients with metastatic RCC was recently reported
[24], the clinical efﬁcacy of this combination remains to be
conﬁrmed. Jonasch et al. reported that the outcome after
addition of IFN-a to sorafenib was comparable to that of
sorafenib monotherapy, when patients were randomized to
treatment with either sorafenib (400 mg twice daily) or the
combination of sorafenib (400 mg twice daily) plus IFN-a
(0.5 MU twice daily) [25]. However, their IFN-a dose of 1
million units daily was probably too low to assess its
additive effect because the average dose is 3–9 million
units daily. So far, the published studies on combination
therapy with IFN-a and sorafenib have employed
Fig. 10 Survival curve in the patients with metastatic lesions (M1)
based on the mean values of mRNA levels of serum and tumor
lFNAR2 s, and of protein levels of tumor phosphorylated Akt (Ser-
473) and phosphorylated S6 ribosomal protein (Ser-235/236), the
cases were divided into two groups at this levels—high and low
expression. Progression-free survival curve based on serum (a) and
tumor IFNAR2 mRNA levels (b) in M1 patients treated with IFN-a ±
sorafenib therapy. Progression-free survival curve based on tumor
proteins for phosphorylated Akt (Ser-473) (c) and phosphorylated S6
ribosomal protein (Ser-235/236) (d) in M1 patients treated with IFN-
a ? sorafenib therapy. Overall survival curve based on serum (e) and
tumor IFNAR2 mRNA levels (f) in M1 patients treated with IFN-a ±
sorafenib therapy. Overall survival curve based on tumor proteins for
phosphorylated Akt (Ser-473) (g) and phosphorylated S6 ribosomal
protein (Ser-235/236) (h) in M1 patients treated with IFN-a ?
sorafenib therapy. P value was analyzed by log-rank test
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123concomitant therapy with both agents. In contrast, our
treatment strategy was to add sorafenib (400 mg/day) to
IFN-a in RCC patients whose tumors were refractory to
IFN-a alone, i.e., ﬁrst-line IFN-a monotherapy and second-
line combination therapy with IFN-a plus sorafenib [18]. In
the present study, 26 patients had metastatic disease (M1)
at diagnosis. Among them, ﬁve patients showed a good
response to IFN-a alone (IFN-a: CR-PR), 11 patients
showed a good response to IFN-a ? sorafenib (IFN-
a ? Sor: CR-PR, Table 1), and the remaining 10 patients
had stable disease or showed a poor response to IFN-
a ? sorafenib (IFN-a ? Sor: SD-PD, Table 1). Although
half-dose sorafenib (400 mg/day) caused grade 1/2 toxic-
ity, grade 3/4 toxicity was rare in the present study and
such toxicity resolved when patients suspended sorafenib
therapy. The response rate to the combination of IFN-a
plus half-dose sorafenib was 52.4% (11/21 patients resis-
tant to previous IFN-a monotherapy achieved CR or PR),
indicating that sorafenib may be synergistic with IFN-a,
leading to an increase of antitumor activity. Furthermore,
the patients with good response to this combination therapy
had favorable prognosis (Fig. 6). Thus, this combination
seems to be tolerable and could be a useful treatment
option for advanced RCC resistant to IFN-a monotherapy
[18].
Role of the IFNAR2 and mTOR pathways
in progression of RCC
The preoperative serum level of IFNAR2 mRNA was not
correlated with the effect of IFN-a monotherapy, but a
lower tumor tissue level of IFNAR2 mRNA was related to
a better response to IFN-a. The present ﬁnding that a higher
tumor tissue level of IFNAR2 mRNA was associated with a
poor response to IFN-a is consistent with our previous
results [14]. In contrast, regarding the relationship between
IFNAR2 mRNA levels and the effect of combination
therapy with IFN-a plus sorafenib, the preoperative serum
level of IFNAR2 mRNA was higher in the IFN-a ? Sor:
CR-PR group and the IFN-a: CR-PR group than in the IFN-
a ? Sor: SD-PD group (Fig. 6e), while the tumor tissue
level of IFNAR2 mRNA was lower in the IFN-a ? Sor:
CR-PR group and the IFN-a: CR-PR group than in the IFN-
a ? Sor: SD-PD group (Fig. 6f). These ﬁndings suggested
that a different molecular mechanism might be involved in
IFN-a ± Sor: CR-PR group and IFN-a ? Sor: SD-PD
group.
IFNs are pleiotropic cytokines that regulate antiviral,
antitumor, apoptotic, antiangiogenic, and cellular immune
responses via activation of multiple downstream signaling
cascades, including the Janus tyrosine kinase (Jak)-signal
transducer and activator of transcription (STAT) pathway,
the p38 mitogen-activated protein kinase (MAPK)
pathway, and the mTOR pathway [32, 33]. The Jak-STAT
and p38-MAPK signaling pathways have been shown to be
responsible for transcription of the genes encoding proteins
related to the antiviral and/or antiproliferative effects of
IFNs. On the other hand, it has been reported that activa-
tion of the mTOR pathway by IFNs has an important
regulatory role in mRNA translation and induction of the
interferon response [34, 35]. IFN-a-induced tumor cell
apoptosis is also mediated via the mTOR pathway in a
nucleus-independent manner [36, 37]. Moreover, the Jak-
STAT and mTOR pathways act separately from each other
after activation by IFN-a [37]. Thus, it is likely that mTOR
signaling selectively mediates apoptosis and survival.
The rapamycin-sensitive mTOR-raptor (regulatory-
associated protein of mTOR) complex controls cell growth
by regulating protein synthesis, so mTOR-raptor signaling
is a potential antitumor target, and mTOR inhibitors are
currently under investigation for the treatment of various
human cancers. On the other hand, mTOR also interacts
with rictor (rapamycin-insensitive companion of mTOR),
and recent ﬁndings have suggested that the rapamycin-
insensitive effect of mTOR on cell survival is overactive in
many cancers. Thus, mTOR has dual rapamycin-sensitive
(mTOR-raptor complex: mTORC1) and insensitive
(mTOR-rictor complex: mTORC2) functions, indicating
that treatment with rapamycin will not completely inhibit
mTOR activity [38, 39]. Phosphatidylinositol 3‘kinase
(PI3 K), serine/threonine kinase Akt, and the mTOR
pathway are all overactive in human cancers. mTORC1 lies
downstream of PI3 K and is part of a pathway that is
frequently activated in human cancers, so mTORC1
represents a pivotal target for anticancer therapy. The best-
characterized pathways regulated by mTORC1 are phos-
phorylation and activation of ribosomal S6 kinase-1
(S6K1) and phosphorylation and inactivation of 4E-BP1,
the suppressor of mRNA cap-binding protein eIF4E,
leading to effects on cell growth and metabolism by acting
as a restriction point in cells subjected to stresses [40, 41]
such as hypoxia [42–44].
Phosphorylation at two sites is required for full activa-
tion of Akt, since it is phosphorylated by PI3 K-dependent
kinase-1 (PDK1) at a threonine residue in the catalytic
domain (Thr 308) and by PI3 K-dependent kinase-2
(PDK2) at a serine residue (Ser 473) in the carboxy-ter-
minal hydrophobic motif [45]. It has been reported that
mTORC2 regulates the actin cytoskeleton and also pos-
sesses PDK2 activity that phosphorylates Ser-473 in the
carboxy-terminal of Akt, making it essential for Akt
activity [46]. Importantly, activation of Akt may lead to
cell survival when mTORC1 is inhibited or could poten-
tially increase VEGF production because PI3 K/Akt sig-
naling induces tumor angiogenesis by regulating VEGF via
both HIF-1a-dependent and -independent mechanisms
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123[47]. It has been reported that hypoxia-inducible factor
(HIF) 1a expression is dependent on both raptor and rictor,
whereas HIF2a expression only depends on rictor and
HIF2a is more important in RCC [48]. These ﬁndings
suggest that phosphorylation of Ser 473 in AKT is a key
molecular step in the progression of RCC and could be a
target for treating these tumors [25]. In agreement with
this, our current study showed that the tumor tissue levels
of IFNAR2 mRNA and phosphorylated S6 ribosomal
protein (Ser-235/236) were positively correlated and that
both were related to tumor metastatic potential, while a
high phosphorylated Akt (Ser-473) level in the primary
tumor was associated with a poor response to IFN-a ±
sorafenib therapy (stable or progressive disease).
Current efforts to achieve the clinical development of
mTOR inhibitors are based on the role of mTOR signaling
in promoting the proliferation and survival of tumor cells.
It has been reported that treatment with mTOR inhibitors
can improve the outcome of patients with metastatic RCC
[8–10]. On the other hand, the mTOR pathway is also
important for IFN-dependent translational responses, and
IFN-a is widely used to treat advanced RCC. Although we
could not exclude a possible detrimental effect of IFN-a
treatment in the patients with metastatic RCC and higher
IFNAR2 mRNA levels in their tumors, our ﬁndings sug-
gested that there may be different molecular mechanisms
of cancer progression in the patients with a good or poor
response to IFN-a ± sorafenib. It is possible that IFNAR2
signaling has different biological effects from normal when
upregulated in RCC.
Jonasch et al. recently reported that an increase of
phosphorylated Akt (Ser-473) was associated with worse
survival by microarray analysis of parafﬁn-embedded
specimens [25]. In the present study, the tumors with
higher phosphorylated Akt (Ser-473) levels, but not higher
phospho-S6 ribosomal protein (Ser-235/236) levels, were
resistant to IFN-a ± sorafenib therapy. In addition, the
tumor tissue levels of IFNAR2 mRNA and phosphorylated
S6 ribosomal protein (Ser-235/236) were positively corre-
lated, and both were related to metastatic potential. Tumor
levels of IFNAR2 mRNA also had a weak positive corre-
lation with those of phosphorylated Akt (Ser-473). More-
over, the patients whose tumors had higher levels of
phosphorylated Akt (Ser-473), phosphorylated S6 ribo-
somal protein (Ser-235/236), and IFNAR2 mRNA showed
shorter overall survival. Taken together, it is possible that
phosphorylation of Ser 473 on Akt is a key molecular step
in the progression of RCC and a potential therapeutic
target, so that the tumor level of phosphorylated Akt
(Ser-473) may be useful for predicting the response to
treatment. At present, it remains to be elucidated why
upregulation of IFNAR2 expression is linked to the pro-
gression of RCC and to a poor response to treatment, and it
is unclear how IFNAR2 interacts with mTORC1 and
mTORC2, but our ﬁndings suggested that the IFNAR2-
mTORC1 pathway via phosphorylated S6 ribosomal pro-
tein (Ser-235/236) may act locally within tumors to pro-
mote proliferation and metastasis by modifying mRNA
translation, while the IFNAR2-mTORC2 pathway via
phosphorylated Akt (Ser-473) may be associated with
tumor resistance. So, these interactions should be eluci-
dated in the future. As Lekmine et al. have indicated,
therefore, caution should be exercised when designing
clinical trials that combine an mTOR inhibitor and IFN-a
due to possible antagonism of antitumor activity [34]. In
fact, Huges et al. reported that patients treated with
temsirolimus alone had better overall survival than those
given IFN-a alone, while patients treated with temsirolimus
plus IFN-a did not [49]. In the future, the downstream
targets of IFNAR2 should be identiﬁed, and the expression
or activity of one or two such targets should be studied in
cell lines or tissue samples. A better understanding of the
IFNAR2 pathway may help to elucidate its role in cancer.
Although none of our patients were treated by sorafenib
alone, it would be interesting to assess the expression of not
only IFNAR2, phosphorylated Akt (Ser-473), and phos-
phorylated S6 ribosomal protein (Ser-235/236), but also
VEGF receptor and Raf, in tumor cells and the effects of
sorafenib, sunitinib, or mTOR inhibitors. Such information
could lead to elucidation of the role of the IFNAR2-mTOR
pathway in the progression of RCC and the selection of
patients who will beneﬁt from treatment with IFN-a, so-
rafenib, sunitinib, or mTOR inhibitors.
Role of serum IFNAR2 in progression of RCC
The serum CRP level is associated with the stage and
outcome of RCC [50, 51]. Elevation of CRP is primarily
determined by an increase of circulating IL-6 [52], and the
IL-6 level is correlated with the serum CRP level as well as
with tumor histological grade and tumor metastasis [53].
We previously reported that increased serum levels of CRP
and IL-6 were associated with local tumor invasion and
metastasis [54]. In the present study, a higher preoperative
serum CRP level was associated with local invasion and
metastasis of RCC, but not with the response to treatment
(data not shown). These ﬁndings suggest that the serum
CRP level is associated with tumor aggressiveness, so that
elevation of CRP might reﬂect the poorer general condition
of the patient rather than the response to therapy. On the
other hand, IFN-a has immunomodulatory effects and
direct antitumor activity as well as antiangiogenic activity,
including inhibition of VEGF [30]. Therefore, it is unclear
exactly what serum IFNAR2 reﬂects, but it is likely to be
associated with the overall immune status. Accordingly, we
expected to ﬁnd a relation between the preoperative serum
806 Cancer Immunol Immunother (2011) 60:793–808
123levels of IFNAR2 mRNA and CRP, but no relation was
observed.
Although we could not examine how IFN-a binds to
IFNAR2 on peripheral blood cells and then exhibits
antitumor and antiangiogenic activity, our ﬁndings showed
that the preoperative serum level of IFNAR2 mRNA was
positively correlated with tumor size and was higher in
patients with metastatic RCC who showed a good
response to IFN-a ± sorafenib therapy than in those with
a poor response. Because obtaining blood samples from
patients is easier than harvesting tissue samples, chrono-
logical analysis of serum IFNAR2 mRNA levels is pref-
erable for evaluation of the role of IFNAR2. While the
effect of IFN-a therapy on the serum level of IFNAR2
mRNA is still unclear, our chronological evaluation of
IFNAR2 mRNA throughout treatment showed that its
serum level remained higher in the IFN-a ± Sor: CR-PR
group than in the IFN-a ? Sor: SD-PD group. Taken
together, these observations suggest that an increased
serum level of IFNAR2 mRNA may represent a systemic
immunologic and antitumor response to the tumor burden
in RCC patients, as well as showing antimicrobial activity
if infection occurs.
Regarding the effect of genetic polymorphism on the
response of metastatic RCC to IFN-a, it has been reported
that STAT3 polymorphism is a useful diagnostic marker
for predicting the response to IFN-a therapy in these
patients [55]. An efﬁcient marker of the response to IFN-a
is needed to establish individualized optimal treatment
strategies, especially when newer therapies are used as
ﬁrst-line treatment for metastatic RCC. Our study showed
that patients with higher serum levels of IFNAR2 mRNA
may be more likely to respond to IFN-a ± sorafenib
therapy and to show a longer overall survival, while
patients with higher tumor tissue levels of IFNAR2 mRNA
may show poor response and unfavorable overall survival.
Although we need a surgical specimen to examine tumor
tissue levels of IFNAR2 mRNA and protein, the serum
level of IFNAR2 mRNA can be conveniently measured, so
it may be more useful for predicting the response to IFN-a
± sorafenib therapy and as a prognostic indicator.
Conclusion
This study showed that an elevated serum level of IFNAR2
mRNA could predict the response of metastatic RCC to
IFN-a ± sorafenib and may be associated with favorable
prognosis.
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